Abstract
There is no denying that many revolutions took place in the fight against cancer during the last decades. However, cancers have always managed to find new ways to challenge humankinds. Variable genomic epidemiology, socio-economic differences and limitations of widespread screening are the major concerns in cancer diagnosis and early treatment. A multidisciplinary approach is essentially to manage a cancer patient efficiently. Thoracic malignancies including lung cancers and pleural mesothelioma are accountable for little more than 11.6% of the global cancer burden [4]. Mesothelioma is one of the rare cancers, but concern is the incidences are increasing globally. However, the good news is first-line chemotherapy with the combination of immune checkpoints inhibitors (ICIs) in non-small cell lung cancer (NSCLC) and mesothelioma has showed promising respond and improved overall survival (OS) in pivotal clinical trials [10]. ICIs are commonly referred as immunotherapy are antigens on the cancer cells, and inhibitors are the antibodies produce by the T cell defence system. By inhibiting immune checkpoints, the cancer cells become visible to be identified as abnormal cells and attack by the body’s defence system [17]. The programmed death receptor-1 (PD-1) and programmed death receptor ligand-1 (PD-L1) inhibitors are commonly used immune checkpoint blockers for anti-cancer treatment. PD-1/PD-L1 are proteins produced by immune cells and mimic by cancer cells that are implicated in inhibiting T cell response to regulate our immune system, which results tumour cells escaping the defence mechanism to achieve immune surveillance. Therefore, inhibiting immune checkpoints as well as monoclonal antibodies can lead to effective apoptosis of tumour cells [17]. Mesothelioma is an industrial disease caused by significant asbestos exposure. It is the cancer of the mesothelial tissue which presents in the lining of the mediastinum of pleura, pericardium and peritoneum, most commonly affected sites are pleura of the lung or chest wall lining [9] as route of asbestos exposure is inhalation. Calretinin is a calcium binding protein, typically over exposed in malignant mesotheliomas and the most useful marker even while initial changes take place [5]. On the other hand, Wilm’s tumour 1 (WT-1) gene expression on the tumour cells can be related to prognosis as it can elicit immune response, thereby inhibit cell apoptosis. A systematic review and meta-analysis study conducted by Qi et al. has suggested that expression of WT-1 in a solid tumour is fatal however, it gives the tumour cell a feature of immune sensitivity which then acts positively towards the treatment with immunotherapy. Clinical significance of WT-1 oncogene in treatment is still hugely debatable and needs further attention [21]. Recently, Japan has reinstated Nivolumab in patients with chemo-refractory mesothelioma. According to NCCN guidelines, the salvage therapies include Pembrolizumab in PD-L1 positive patients and Nivolumab alone or with Ipilimumab in cancers irrespective of PD-L1 expression [9]. The checkpoint blockers have taken over the biomarker-based research and demonstrated impressive treatment options in immune sensitive and asbestos-related cancers. It can be expected that in near future the immune checkpoint inhibitors will be considered as approved first-line cancer treatment universally.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abreu CE, Ferreira PP, de Moraes FY, Neves WF Jr, Gadia R, Carvalho H (2015) Stereotactic body radiotherapy in lung cancer: an update. Jornal brasileiro de pneumologia: publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia 41(4):376–387. https://doi.org/10.1590/S1806-37132015000000034
Adams K, Shah PL, Edmonds L, Lim E (2009) Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis. Thorax 64(9):757–762. https://doi.org/10.1136/thx.2008.109868
Anagnostou V et al (2020) Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nat Cancer 1:99–111
Baranova K, Cecchini M (2021) Small cell carcinoma of the lung. MyPathologyReport.ca. https://www.mypathologyreport.ca/small-cell-carcinoma-of-the-lung/. Last Accessed 1 Oct 2021
Doglioni C, Dei A, Laurino L, Iuzzolino P, Chiarelli C, Celio M, Viale G (1996) Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 20(9):1037–1046. https://doi.org/10.1097/00000478-199609000-00001
De Gooijer CJ et al (2020) Immunotherapy in malignant pleural mesothelioma. Front Oncol 10:187
Farid S, Lui SV (2020) Chemo-Immunotherapy as first-line treatment for small cell lung cancer. Ther Adv Med Oncol
Ferrell B, Koczywas M, Grannis F, Harrington A (2011) Palliative care in lung cancer. Surg Clin North Am 91(2):403–417. https://doi.org/10.1016/j.suc.2010.12.003
Forde PM, Scherpereel A, Tsao AS (2019) Use of immune checkpoint inhibitors in mesothelioma. Curr Treat Options Oncol 20(2):18. https://doi.org/10.1007/s11864-019-0613-x
Hann CL, Scherpereel A, Hellyer JA, Wakelee HA (2019) Role of immunotherapy in small cell lung cancer, thymic epithelial tumors, and mesothelioma. Am Soc Clin Oncol Educ Book 39:543–552. https://doi.org/10.1200/EDBK_237847
Hayashi K, Nakagawa K (2020) Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol 5:818–830
Isaka T, Nakayama H, Yokose T, Ito H, Katayama K, Yamada K, Masuda M (2017) Platinum-based adjuvant chemotherapy for stage II and stage III squamous cell carcinoma of the lung. Ann Thorac Cardiovasc Surg 23(1):19–25. https://doi.org/10.5761/atcs.oa.16-00164
Jiang X et al (2020) Assessment of long-term survival of cancer patients using cancer registry data from eastern China: period analysis is superior to traditional methods. Int J Cancer 147(4):996–1005
Kalemkerian GP, Akerley W, Bogner P et al (2013) Small cell lung cancer. J Natl Compr Canc. Netw: JNCCN 11(1):78–98. https://doi.org/10.6004/jnccn.2013.0011. PMID: 23307984; PMCID: PMC3715060
Kondola S, Manners D, Nowak AK (2016) Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis 10(3):275–288. https://doi.org/10.1177/1753465816628800
Liam CK, Andarini S, Lee P, Ho JC, Chau NQ, Tscheikuna J (2015) Lung cancer staging now and in the future. Respirology 20(4):526–534. https://doi.org/10.1111/resp.12489
Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R (2019) Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers (Basel) 11(11). https://doi.org/10.3390/cancers11111756
Nagasaka M, Gadgeel SM (2018) Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther 18(1):63–70. https://doi.org/10.1080/14737140.2018.1409624
Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Bille A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW (2016) Staging, prognostic factors committee AB, participating I, staging, prognostic factors committee advisory B, participating I. The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol 11(12):2089–2099. https://doi.org/10.1016/j.jtho.2016.08.147
Popat S, Curioni-Fontecedro A, Dafni U, Shah R, O'Brien M, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O (2020) A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 31(12):1734–1745. https://doi.org/10.1016/j.annonc.2020.09.009
Qi X, Zhang F, Wu H, Liu J, Zong B, Xu C, Jiang J (2015) Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep 5(1). https://doi.org/10.1038/srep08924
Wu L, Yun Z, Tagawa T et al (2012) CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol Cancer Ther 11:1809–1819
Xia L et al (2019) PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 24(1):31–41
Zhang S, Li S, Cheng Y (2020) Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer 11(12):3536–3546. https://doi.org/10.1111/1759-7714.13698
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tamanna, M.T., Egbune, C. (2023). Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma. In: Qazi, A.S., Tariq, K. (eds) Therapeutic Approaches in Cancer Treatment. Cancer Treatment and Research, vol 185. Springer, Cham. https://doi.org/10.1007/978-3-031-27156-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-031-27156-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-27155-7
Online ISBN: 978-3-031-27156-4
eBook Packages: MedicineMedicine (R0)